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 CURRENTOPINION Amyotrophic lateral sclerosis: recent genetic
highlights
Matthew A. White and Jemeen Sreedharan
Purpose of review
Amyotrophic lateral sclerosis (ALS), like other neurodegenerative diseases, remains incurable, but gene
mutations linked to ALS are providing clues as to how to target therapies. It is important for researchers to
keep abreast of the rapid influx of new data in ALS, and we aim to summarize the major genetic advances
made in the field over the past 2 years.
Recent findings
Significant variation in seven genes has recently been found in ALS: TBK1, CCNF, GLE1, MATR3, TUBA4A,
CHCHD10 and NEK1. These have mostly been identified through large exome screening studies, though
traditional linkage approaches and candidate gene screening remain important. We briefly update C9orf72
research, noting in particular the development of reagents to better understand the normal role of C9orf72
protein.
Summary
Striking advances in our understanding of the genetic heterogeneity of ALS continue to be made, year on
year. These implicate proteostasis, RNA export, nuclear transport, the cytoskeleton, mitochondrial function,
the cell cycle and DNA repair. Functional studies to integrate these hits are needed. By building a web of
knowledge with interlinked genes and mechanisms, it is hoped we can better understand ALS and work
toward effective therapies.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most com-
mon motor neuron disease of adults and is invar-
iably fatal, often within 5 years of disease onset.
Importantly, ALS is on a clinical, genetic and patho-
logical spectrum with frontotemporal dementia
(FTD). Riluzole, a glutamatemodulator and the only
disease-modifying agent widely used for ALS, has
only a modest effect on survival. Knockdown gene
therapies hold promise for those individuals with
ALS-causing gene mutations in SOD1 and C9orf72,
and clinical trials are underway. However, the
majority of ALS is not caused by mutations in these
or other identified genes. These apparently sporadic
amyotrophic lateral sclerosis (sALS) cases account
for around 90% of all ALS, whereas familial amyo-
trophic lateral sclerosis (fALS), usually dominantly
inherited, accounts for the remainder.
The distinction between sALS and fALS, though
practical, is increasingly recognized to be artificial,
but what is important is that sALS and fALS are often
indistinguishable. This suggests that ALS-linked
genes in rare fALS cases can inform our understand-
ing of sALS. With this in mind, the dizzying pace of
gene discovery in ALS in the past 10 years is to be
welcomed, and advances in exome and genome
sequencing strategies have been invaluable in this
task. Identifying genetic risk factors and modifiers
that influence ALS risk in sALS is also adding to our
understanding of the mechanisms underlying ALS
as a whole.
In this review, we will highlight the latest devel-
opments in the genetics of ALS focussing on genes
identified in the past 2 years. Refer to Table 1 for a
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summary of the genes primarily discussed in this
article. We will then highlight recent advances in
our understanding of C9orf72, still the hottest topic
in the field. Readers are encouraged to refer to the
Amyotrophic Lateral Sclerosis Online Genetics
Database website (http://alsod.iop.kcl.ac.uk/) for a
comprehensive list of other ALS genes or Table 2 for
a summary.
NEW ALS GENES
TBK1
Perhaps the most significant recent genetic discov-
ery in ALS since C9orf72 has been the identification
of mutations in the TBK1 gene (encoding TANK
binding kinase 1). One study examined 2869 ALS
patients and 6405 controls and found nearly 50
variants throughout TBK1 in ALS patients, includ-
ing splice-site, loss-of-function (LoF) and missense
mutations [1
&
]. Another study used whole exome
sequencing and linkage analysis to interrogate 252
fALS cases that were negative for SOD1 and C9orf72
mutation [2
&&
]. In this study, eight predicted LoF
mutations in TBK1 were found in 13 families
(a mixture of truncating and splice-site mutations).
The mean age of onset of fALS was 60 years of age,
15% with bulbar onset and with 50% of cases
demonstrating cognitive impairment, often frank
FTD. LoF mutations were not a contributor to sALS,
but nine missense variants were found in both fALS
and sALS.
The TBK1 LoF mutations would be predicted
to truncate TBK1, but seven of the eight variants
identified by Freischmidt et al. produced little or
no detectable transcripts or protein products,
suggesting that haploinsufficiency of TBK1 is respon-
sible for neurodegeneration. The most 30 truncation
mutation [c.2138þ2T>C (p.690–713del)] generated
a protein product lacking 22 amino acids from the
C-terminal coiled-coil domain 2, which appeared to
abolish its ability to bind optineurin (OPTN) in vitro.
Several of themissense mutations also abrogated the
ability of TBK1 to bind OPTN and/or phosphorylate
IRF3. It remains unclear how loss of TBK1 function
causes neurodegeneration, but aberrant cellular
clearance is a possibility given that both OPTN and
p62, another ALS-linked protein that TBK1 interacts
with, have roles in autophagy [3,4].
TBK1 interacts with OPTN, which binds to ubiq-
uitin chains on mitochondria. This recruits TBK1 to
mitochondria and promotes its kinase activation.
TBK1 can then phosphorylate the UBAN domain of
OPTN, expanding its ability to bind ubiquitin
chains. This positive feedbackmechanism promotes
recruitment and retention of TBK1/OPTN to dam-
agedmitochondria [5]. Further evidence for a role of
TBK1/OPTN in the removal of damaged mitochon-
dria involves the PINK1-PARKIN pathway and
mitophagy through the polyubiquitination of
defective mitochondria. TBK1 physically associates
with autophagy adapters OPTN, NDP52 and p62,
strengthening the link between ALS and selective
autophagy [6], and TBK1 is able to phosphorylate
p62 at S403 in the early period of mitochondrial
depolarization [7].
Further TBK1 variants have recently been found
in European, Taiwanese and Chinese patients with
ALS and/or FTD [8–11]. Strikingly, up to 10.8% of
cases of patients presenting with ALS–FTD in a
French patient cohort were found to carry LoF
mutations in TBK1, suggesting that patients
KEY POINTS
 The exponential rise in genetic discovery in ALS
continues unabated and will continue to do so for
some time.
 New genes implicate proteostasis, RNA export, nuclear
transport, the cytoskeleton, mitochondrial function, the
cell cycle and DNA repair.
 Novel and sophisticated approaches are needed to
integrate and model this new knowledge to identify
therapeutic targets.
Table 1. Article overview
We aim to summarize the major genetic advances in the field of
ALS over the past 2 years:
Significant variation in seven genes have recently been found in
ALS:
TBK1 (TANK binding kinase 1) mutations implicate abnormal
cellular clearance in ALS and TBK1-ALS could be seen as yet
another ‘TDP-43 proteinopathy’
CCNF encodes cyclin F and implicates abnormal protein
ubiquitination and possible aberrant cell cycle re-entry as
mechanisms of neuronal loss in ALS
GLE1 encodes two isoforms involved in multiple cellular
functions including nuclear export and stress granule function
MATR3 mutations have been implicated in ALS. Matrin 3 is a
125-kDa nuclear matrix protein that binds DNA and RNA
TUBA4A encoding the Tubulin, Alpha 4A protein further
implicates cytoskeletal structural dynamics in ALS pathogenesis
CHCHD10 mutations further implicate mitochondrial
dysfunction in ALS
NEK1 mutations are of interest as NEK1 interacts with two
known ALS proteins, Alsin and VAPB
Advances in our understanding of C9orf72 are discussed
covering possible mechanisms of disease, development of tools
to further study the gene and oligogenicity in ALS
ALS, amyotrophic lateral sclerosis.
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presenting with FTD and ALS who do not have
C9orf72 mutations should be screened for TBK1
mutations [12]. In another study of 104 patho-
logically confirmed FTLD-TDP patients who were
negative for C9orf72 and GRN mutations, 4.8% of
patients had mutations in TBK1, OPTN or both [13].
These mutations were associated with reduced
expression of TBK1 and/orOPTNmRNA and protein
in cerebellar tissue. This study implicates the OPTN/
TBK1 pathway in FTD with TDP-43 inclusions [13].
Pathological analysis of brain and spinal cord from
ALS patients with TBK1 mutations also identified
TDP-43 positive inclusions [11,14]. Thus, TBK1-ALS
is yet another ‘TDP-43 proteinopathy’.
CCNF
Linkage analysis followed by whole-exome sequenc-
ing of a large ALS–FTD kindred of British ancestry
Table 2. Genes implicated in amyotrophic lateral sclerosis
ALS type Gene ID Description Location
ALS 1 SOD1 Superoxide dismutase 1, soluble 21q22.11
ALS 2 ALS2 ALS2, alsin Rho guanine nucleotide exchange factor 2q33.2
ALS 3 ALS3 Amyotrophic lateral sclerosis 3 (autosomal dominant) 18q21
ALS 4 SETX Senataxin 9q34.13
ALS 5 SPG11 Spastic paraplegia 11 (autosomal recessive) 15q14
ALS 6 FUS FUS RNA binding protei 16p11.2
ALS 7 ALS7 Amyotrophic lateral sclerosis 7 20p13
ALS 8 VAPB VAMP (vesicle-associated membrane protein) associated protein B and C 20q13.33
ALS 9 ANG Angiogenin 14q11.1
ALS 10 TARDBP TAR DNA binding protein 1p36.22
ALS 11 FIG4 FIG4 phosphoinositide 5-phosphatase 6q21
ALS 12 OPTN Optineurin 10p13
ALS 13 ATXN2 Ataxin 2 12q24.1
ALS 14 VCP Valosin containing protein 9p13.3
ALS 15 UBQLN2 Ubiquilin 2 Xp11.21
ALS 16 SIGMAR1 Sigma nonopioid intracellular receptor 1 9p13.3
ALS 17 CHMP2B Charged multivesicular body protein 2B 3p11.2
ALS 18 PFN1 Profilin 1 17p13.3
ALS 19 ERBB4 erb-b2 receptor tyrosine kinase 4 2q33.3-q34
ALS 20 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 12q13.1
ALS 21 MATR3 Matrin 3 5q31.2
ALS–FTD1 C9orf72 Chromosome 9 open reading frame 72 9p21.2
ALS–FTD2 CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10 22q11.23
ALS UNC13A unc-13 homolog A (C. elegans) 19p13.11
ALS DAO D-amino-acid oxidase 12q24
ALS DCTN1 Dynactin subunit 1 2p13
ALS NEFH Neurofilament, heavy polypeptide 22q12.2
ALS PRPH Peripherin 12q13.12
ALS SQSTM1 Sequestosome 1 5q35
ALS TAF15 TATA-box binding protein associated factor 15 17q12
ALS SPAST Spastin 2p24-p21
ALS ELP3 Elongator acetyltransferase complex subunit 3 8p21.1
ALS LMNB1 Lamin B1 5q23.2
GLE1 GLE1 RNA export mediator 9q34.11
TBK1 TANK binding kinase 1 12q14.1
TUBA4A Tubulin alpha 4a 2q35
CCNF Cyclin F 16p13.3
NEK1 NIMA related kinase 1 4q33
ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia.
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identified a missense mutation in the CCNF gene
[15
&&
]. Further novel CCNF variants were identified
through screening additional fALS (600), sALS
(500) and FTD (nearly 200) cases from Europe,
North America, Japan and Australia. Five novel mis-
sense mutations were found in familial ALS and/or
FTD, and 19 mutations (missense, nonsense and
frameshift) were seen in sporadic ALS and/or FTD.
Most mutations affected highly conserved residues,
and none were seen in controls. No clear genotype–
phenotype pattern was evident. An additional rep-
lication study of 611 sALS cases and 1424 controls
demonstrated an enrichment of mutations in ALS.
In summary, mutations in CCNF occur throughout
the world and account for 0.6–3.3% of fALS cohorts.
CCNF encodes cyclin F, a ubiquitously expressed
protein, which is known to function in two major
biological processes. First, cyclin F helps to form an
E3 ubiquitin-protein ligase complex and transfer
activated ubiquitin to target proteins for degra-
dation. Overexpression of ALS mutant cyclin F
isoforms appeared to result in an increase in ubiq-
uitinated proteins and, notably, an increase in TDP-
43 ubiquitination [15
&&
]. Whether the underlying
mechanism is due to a toxic gain of function and
whether cyclin F-linked ALS is a ‘TDP-43 proteinop-
athy’ in vivo are important questions requiring
further investigation.
Cyclin F also has a role in coordinating the cell
cycle. Cyclin F levels rise through interphase, peak-
ing inG2 and then dropping atmitosis [16]. Cyclin F
is not a highly abundant protein and appears
unstable. Unlike other cyclins, its degradation is
independent of the ubiquitin proteasome system
but requires the C-terminal PEST region of the
protein [17]. Cyclin F is a substrate binding subunit
of SCF (Skp1-Cul1-F-box protein) ubiquitin ligase
complexes and interacts with the ribonucleotide
reductase family member 2. Ribonucleotide
reductase plays a critical role in the conversion of
ribonucleotides to deoxyribonucleotides necessary
for replicative and repair DNA synthesis.
Attempts by postmitotic neurons to re-enter the
cell cycle can lead to apoptosis and neuronal loss
characterized by increased expression of cyclins. In a
neurotrophin withdrawal model of primary motor
neuron apoptotic cell death, nuclear condensation
and DNA fragmentation can be observed along with
activation of caspase-3 and caspase-9. The cyclin-
dependent kinase inhibitors olomoucine, roscovi-
tine and flavopiridol have been demonstrated to
suppress the death of motoneurons. Taken together
with the observation that cyclin D1 and cyclin E
expression rises following removal of neurotrophic
support, it can be envisaged that postmitotic
neuronal loss occurs as neurons attempt to re-enter
the cell cycle inappropriately [18]. Treatment with
nerve growth factor decreases cyclin F levels in
PC12EY cells suggesting that cyclin F is involved
in NGF-mediated cell cycle events during the differ-
entiation of these cells [19].
GLE1
Recessive mutations in GLE1, encoding the RNA-
processing protein Gle1, cause the lethal congenital
contracture syndrome 1 and lethal arthrogryposis
with anterior horn cell disease [20,21]. Candidate
screening ofGLE1 in 173 fALS and 760 sALS patients
recently identified novel nonsense and missense
mutations in two sALS cases and a splice-site
mutation in a fALS case [22
&&
]. The nonsense trans-
cript produces no functional protein, whereas the
splice-site mutation alters the C-terminus, prevent-
ing the mutant isoform from localizing at the
nuclear pore where it is critical for mRNA export.
These GLE1 mutants also failed to rescue motor
neuron pathology in zebrafish lacking GLE1. Thus,
the mutations seem to cause a critical loss
of function.
GLE1 encodes two isoforms, Gle1A and Gle1B.
Gle1B localizes to the nuclear pore complex and
shuttles between the nucleus and cytoplasm [23]
and self-associates via its coiled-coil domain form-
ing oligomers necessary for its function in mRNA
export [24]. The unique C-terminal 43 amino acid
region of Gle1B mediates binding to the C-terminal
non-FG region of the nucleoporin CG1/NPL1 [23],
whereas nuclear rim localization of Gle1B is depend-
ent on 29 N-terminal residues that interact with
Nup155 [25]. These observations are interesting
given that nuclear transport has recently been impli-
cated in motor neuron degeneration [26,27].
Gle1 also has important roles in translation
termination [28,29] and initiation [30]. Interest-
ingly, the Gle1A isoform specifically has been found
to associate in stress granules, which is an area of
intense research in ALS [31]. Furthermore, overex-
pression of Gle1A or a disease-associated isoform led
to the formation of cytoplasmic protein aggregates
[32]. This suggests that, rather than loss of function,
cellular stress may occur through increased cyto-
plasmic Gle1 activity.
MATR3
Exome sequencing of a family of European ancestry
with dominantly inherited ALS and dementia ident-
ified amutation in theMATR3 gene causing a F115C
missense change [33
&&
]. Analysis of a further 108
fALS cases identified a T622A mutation in a 66-year-
old Sardinian and a first cousin who presented with
Nerve, neuro-muscular junction and motor neuron diseases
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rapidly progressive ALS at 64 years of age. Analysis
of 96 British ALS cases identified a P154S variant
in a sALS case. Further large screens of European,
Canadian and Australian ALS cohorts identified
three variants in MATR3 including a V394M
missense mutation and two splice-site mutations
[34–36], whereas a Taiwanese study of 200 cases
found just one mutation (A72T) in a patient with
bulbar-onset ALS [37]. Overall, MATR3 mutations
may account for less than 1% of ALS. Interestingly,
there is clinical heterogeneity in the phenotype
associated with MATR3 mutations, with some cases
having very slow progression longer than 15 years,
or clinical and electromyographic findings more in
keeping with distal myopathy with vocal cord pare-
sis [38–40].
Matrin 3 is a 125-kDa nuclear matrix protein
that binds DNA and RNA. It remains unclear how
ALS-linked mutations might cause disease, with
initial pathological and cellular studies showing
little or no mislocalization of matrin 3 [33
&&
,41].
There is some evidence that TDP-43 and matrin
3 may interact [42] but more work is needed
to determine if MATR3-ALS is indeed a TDP-43
proteinopathy.
TUBA4A
Identification of TUBA4A (encoding the Tubulin,
Alpha 4A protein) as a candidate gene associated
with fALS is intriguing as it further implicates cyto-
skeletal structural dynamics in ALS pathogenesis
[43
&&
]. Exome sequencing and rare variant analysis
of a discovery cohort identified five nonsynony-
mous TUBA4A changes within exon 4. These
changes included four missense variants – R320C/
H, R215C, A383T and a nonsense mutationW407X.
Four of these mutations were predicted to be dele-
terious, whereas three nonsynonymous changes
found in 4300 controls were predicted to be benign.
A replication study revealed an excess of TUBA4A
mutations among patients and identified a T145P
variant that segregated with disease. With the
exception of A383T and G43V, no ALS-associated
TUBA4A mutations were seen in 13023 controls.
Clinically, patients with TUBA4Amutations display
spinal-onset ALS with both upper and lower motor
neuron features with a low prevalence of FTD. Time
will tell how common a cause of ALS TUBA4A
mutations are.
In-vitro studies suggested that TUBA4A
mutations confer a dominant-negative property
on the protein. Mutant TUBA4A is inefficient at
forming a-tubulin/b-tubulin dimers and poorly
incorporates intomicrotubules in vitro. Variants also
inhibit the general assembly of the cellular
microtubule network and thus reduce structural
stability. TUBA4AW407X can form aggregates and
therefore may sequester other tubulin binding
proteins or impair cellular proteostasis.
CHCHD10
Bannwarth et al. [44
&&
] described a large kindredwith
slowly progressive ALS, FTD, cerebellar ataxia, mito-
chondrial myopathy and mitochondrial DNA
deletions. Failing to identify mutations in genes
normally associated with mitochondrial disease,
they undertook whole exome sequencing and ident-
ified a missense mutation in CHCHD10 (c176C>T;
p.S59L), which encodes the coiled-coil helix
domain-containing protein 10. This same mutation
was also identified in another kindred with classical
ALS–FTD, with or without Parkinsonism.
CHCHD10 is a mitochondrial protein located in
the intermembrane space and enriched at cristae
junctions. Both endogenous and overexpressed
CHCHD10S59L altered mitochondrial cristae ultra-
structure and caused fragmentation of the mito-
chondrial network. Respiratory chain deficiency
was also observed, suggesting that CHCHD10 is
critical for maintaining ATP production and oxygen
consumption [44
&&
]. Mitochondria from CHCHD10
mutant fibroblasts also showed poor genome repair
after oxidative stress [45].
Subsequent studies have identified CHCHD10
mutations in European populations in association
with a variety of phenotypes, mostly ALS and FTD,
but also Charcot–Marie–Tooth type 2 and spinal
muscular atrophy [46–55]. In these populations,
CHCHD10 mutation accounts for less than 1% of
ALS and FTD. Interestingly, studies from China
suggest that although CHCHD10mutations are also
rare in ALS, they may be a more significant cause of
FTD, perhaps accounting for nearly 10% of cases in
this population [56–58].
NEK1
Another minor hit from the exome sequencing
study of Cirulli et al. [1
&
] was dominant LoF
mutations in NEK1. More recently, this gene was
implicated in a separate whole exome sequencing
study of 265 fALS index cases and 827 control
individuals [59]. More screens will help determine
how common a cause of ALS and/or FTD NEK1
mutations are, but it is notable that initial studies
suggest that NEK1 interacts with two known ALS
proteins, Alsin and VAPB [1
&
].
Other studies have shown that the C21orf2
protein can interact with NEK1. C21orf2 affects cell
proliferation after DNA damage. DNA repair was
ALS: recent genetic highlights White and Sreedharan
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shown to be less efficient in C21ORF2-depleted cells
and homologous recombination was impaired. This
deficit could be rescued by the overexpression of
NEK1 [60]. NEK1 is a member of the NIMA (never in
mitosis A) related kinase family of serine/threonine
kinases involved in the early cellular response to
genotoxic stress and plays an important role in
preventing cell death induced by DNA damage
[61,62]. Foci of damaged DNA in NEK1 null cells
remain after removal of a toxic insult, andNEK1 null
cells develop unstable chromosomes at a rate much
higher than identically cultured wild-type cells [63].
NEK1 also plays a role in mitochondrial function
regulating a pathway of mitochondrial cell death
through phosphorylation of voltage-dependent
anion channel 1 (VDAC1) on serine 193 [64].
LATEST DEVELOPMENTS IN C9orf72
The C9orf72 gene remains the most lucrative area of
research in ALS right now. The astounding progress
in our understanding of C9orf72 biology is due to
the novelty of the gene mutation, an intronic hex-
anucleotide repeat expansion (HRE) and myriad
questions regarding its mode of toxicity; the fre-
quency of the mutation, which accounts for
22–61% of fALS, 6–19% of sALS and around 25%
of familial FTD in European populations; the fact
that C9orf72 mutation is associated with TDP-43
pathology, the hallmark protein of ALS and half
of FTD cases and the fact that C9orf72 links both
ALS and FTD, which are on a clinicopathological
spectrum. The history and progress of ‘C9-ALS–FTD’
have recently beenwell reviewed elsewhere [65–67],
but a few points are worthy of note.
(1) Although the debate over protein (dipeptide
repeats, DPRs, generated by RAN translation)
and RNA toxicity (RNA foci, G-quadruplexes,
sequestration of RNA-binding proteins) in C9-
ALS–FTD continues, mouse knockout studies
have shown that loss of C9orf72, while not
obviously toxic to the nervous system, can cause
severe immune dysregulation and lymphoma
[68–70]. One study suggested a role for
C9orf72 in autophagy [71]. It has therefore been
suggested that human C9orf72 knockdown
therapies should specifically target the HRE-
containing allele to avoid the potential effects
of complete loss of C9orf72.
(2) The recent development of novel antibodies
directed against the short and long isoforms
of the C9orf72 protein is welcome [72
&&
]. These
tools demonstrated that the long isoform is
present in the cytoplasm in vivo. The short iso-
form localizes to the nuclear membrane, but in
ALS patients it seems to relocate to the plasma
membrane, and in these cells TDP-43 mislocal-
izes as well [72
&&
]. These results are intriguing
given recent interest in nucleocytoplasmic
transport disruption in models of C9orf72
mutation (reviewed in [27]). More experimental
tools are needed to elucidate the normal func-
tions of C9orf72 protein, whose biology remains
poorly understood.
(3) Novel transgenic mouse models have recently
been developed, which variably recapitulate fea-
tures of ALS [73–76,77
&&
]. One BAC-transgenic
model in particular develops physical and
pathological phenotypes relevant to human dis-
ease, including, importantly, TDP-43 proteinop-
athy [77
&&
]. Intriguingly, this model found that
antisense transcripts were better correlated with
disease than sense transcripts. These models
may prove valuable in developing biomarkers
and therapies for ALS–FTD.
(4) Oligogenicity in ALS is a topic of growing inter-
est and appears to be more common in fALS
than sALS [78]. One particularly interesting
example is the coexistence of intermediate
expansions in ATXN2 with the C9orf72 HRE
[78–80]. It has been suggested that ATXN2
expansion may push C9orf72 HRE carriers
toward an ALS or ALS–FTD phenotype rather
than one of the many other phenotypes associ-
ated with the mutation. Further genotype–phe-
notype studies are warranted, as determining
how oligogenicity in ALS modifies phenotypes
will no doubt lead to important insights into
disease pathogenesis and yield credible thera-
peutic targets.
CONCLUDING REMARKS
Significant genetic advances continue to be made in
ALS as we have summarized above. These clues
implicate almost every area of cell biology, in
particular proteostasis, RNA processing and the
neuronal cytoskeleton. Having focussed our atten-
tion on these new genes, and advances in C9orf72,
we have not had an opportunity to describe a num-
ber of other intriguing advances made in our under-
standing of established ALS genes. These include a
potential role for TDP-43 in cryptic exon splicing
[81], hydrogel studies of hnRNPs, DPRs and FUS,
which show that ALS mutations can impair proteo-
stasis and axonal local translation [82–85], the
characterization of the first SOD1 ENU mutant
knock-in mouse that develops a motor phenotype
[86] and a large Turkish study identifying a number
of intriguing new rare variants in ALS cases [87].
Thanks to project MinE (www.projectmine.com)
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and other gene-hunting projects, we are set to
identify yet more ALS-causing genes. These genetic
discoveries clearly indicate the complexity of the
mammalian motor system and how it can be made
to suffer in so many different ways. However daunt-
ing this complexity may seem, our growing know-
ledge will empower us to accelerate progress toward
finding ways to slow and potentially halt the neuro-
degeneration that occurs in ALS.
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